MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Subscribe To Our Newsletter & Stay Updated